All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.
TRANSLATE
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View GvHD content recommended for you
ASH Congress 2022
28 Feb 2023
#ASH22 | Ulschmid presented the first widely inclusive, validated, clinical risk score for predicting the risk of developing Grade II–IV and III–IV aGvHD after allo-HCT.
Read more 👉 https://t.co/YSkbsSs8SS
#gvhd #BMTSM
Read more 👉 https://t.co/YSkbsSs8SS
#gvhd #BMTSM
6 Feb 2023
🎥 #ASH22 | The GvHD Hub was pleased to speak to Annie Im, University of Pittsburgh, Pittsburgh, US. We asked about itacitinib and corticosteroids for chronic GvHD.
Watch the full interview here: https://t.co/xsgYT5pO1r
#gvhd #gvhdsm @PittTweet
Watch the full interview here: https://t.co/xsgYT5pO1r
#gvhd #gvhdsm @PittTweet
3 Feb 2023
#ASH22 | 🎥 During the 64th ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, What is the latest update on the GRAVITAS-309 trial?
Watch the full video here 👇
https://t.co/EETStJLMmO
Watch the full video here 👇
https://t.co/EETStJLMmO
1 Feb 2023
#ASH22 | Mark Schroeder discussed a phase I study of baricitinib for acute #GvHD in patients receiving PBSCT. The overall survival at 1 year was 71%, with no cases of graft failure.
See our latest article for a summary: https://t.co/nZseor6L1Q
#bmtsm
See our latest article for a summary: https://t.co/nZseor6L1Q
#bmtsm
27 Jan 2023
#ASH22 | Liu discussed ruxolitinib + steroids compared with steroids alone as a first-line treatment for high-risk aGvHD. The rate of failure-free survival was found to be significantly higher in the ruxolitinib group.
Read more 👉 https://t.co/OaVTAH57ub
#bmtsm #GvHD
Read more 👉 https://t.co/OaVTAH57ub
#bmtsm #GvHD
20 Jan 2023
#ASH22 | @Mohty_EBMT discussed MaaT013 for the treatment of GI-aGvHD. At Day 28, overall response was 49% and 56% of patients achieved a GI overall response.
Read more: https://t.co/657Q0dsssV
#GvHD #gvhdsm #bmtsm
Read more: https://t.co/657Q0dsssV
#GvHD #gvhdsm #bmtsm
6 Jan 2023
🎥 #ASH22 | The GvHD Hub was pleased to speak to Annie Im, University of Pittsburgh, Pittsburgh, US. We asked about itacitinib and corticosteroids for chronic GvHD.
Watch the full interview here 👇 #gvhd #gvhdsm @PittTweet
https://t.co/l1g7iBg4be
Watch the full interview here 👇 #gvhd #gvhdsm @PittTweet
https://t.co/l1g7iBg4be
14 Dec 2022
#ASH22 | 🎥 During the 64th ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, What is the latest update on the GRAVITAS-309 trial?
Watch the full video here 👇
https://t.co/rca67cglYw
Watch the full video here 👇
https://t.co/rca67cglYw
14 Dec 2022
We hope you enjoyed following our live updates and congress coverage from #ASH22!
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #gvhd
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #gvhd
13 Dec 2022
RT @MM_Hub: CONGRESS | #ASH22
@profshanecrotty of the @ljiresearch institute speaks on SARS-CoV-2 and vaccinations in terms of immune respo…
@profshanecrotty of the @ljiresearch institute speaks on SARS-CoV-2 and vaccinations in terms of immune respo…
13 Dec 2022
RT @MPN_Hub: CONGRESS | #ASH22
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRN…
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRN…
13 Dec 2022
CONGRESS #ASH22 | @sghmd @umnmedschool presents the LBA on a phase III trial BMTCTN1703 of PTCy/Tac/MMF vs Tac/MTX for #GvHD prophylaxis. N=431. PTCy grp had a sig lower HR of GRFS vs Tac/MTX (HR 0.641). The adjusted 1-yr GRFS rate =52.7% for the PTCy arm & 34.9% for the ctrl arm
13 Dec 2022
It’s the last day of #ASH22.
Don’t miss out on our final live updates!
Today’s session:
Late breaking abstracts
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #gvhd
Don’t miss out on our final live updates!
Today’s session:
Late breaking abstracts
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #gvhd
12 Dec 2022
CONGRESS #ASH22 | @RichardChamplin @MDAndersonNews reports on a phase I in human study of antiviral veto cells allowing engraftment without severe #GvHD N=10. All pts engrafted. Only 1 developed steroid-responsive, gr 2 GVHD of the skin, No tox related to the veto cells occurred
12 Dec 2022
CONGRESS #ASH22 | Michelle Chin @ourmedschool @StanfordMed presents data on belumosudil & several combos with ruxo, ECP, pred, sirolimus or CNI for patients with SR or SD cGvHD. N = 26. ORR following the addition of belumosudil = 77%. Infectious AEs = 42% #GvHD #BMTSM
12 Dec 2022
CONGRESS #ASH22 | Yi-Bin Chen @MassGeneralNews speaks about RGI-2001 a liposomal glycolipid for the prevention of aGvHD in a phase IIb study with CNI+MTX/MMF N=49. Day-180 estimates of OS, grades II-IV acute GFS, and relapse were 93.9%, 75.5%, & 6.1%, respectively. #GvHD #BMTSM
12 Dec 2022
CONGRESS #ASH22 | Mark A Schroeder @WashUHeme discusses a phase I study of baricitinib as GvHD prophylaxis in HLA-matched PBSC-HCT. N=24. TRM at D180 was 8%. The CI of grade III/IV aGVHD at day 100 =4% & the overall incidence of grade III/IV aGVHD at any time =12.5% #GvHD #BMTSM
12 Dec 2022
CONGRESS #ASH22 | @MPN_BMTDOC @cityofhope reports on a phase IIa study of ita+Tac/Siro in pts receiving PBSC-HCT from a matched donor. N=59. At 5.9 months FU, all-cause mortality was n=9, NRM=6, gr 3-4 acute GVHD (n=5), mod/severe cGVHD (n=2), & disease relapse (n=8) #GvHD #BMTSM
12 Dec 2022
CONGRESS #ASH22 | @annieimmcl @UPMC presents results from Gravitas-309 study of itacitinib +corticosteroids (CS) as 1st line treatment for mod/severe cGvHD. N=139. ORR at 6 months was 46% (CR, 14%) with 300mg qd & 53% (CR, 32%) with 400mg qd, vs 36% (CR, 18%) with CS #GvHD #BMTSM
12 Dec 2022
CONGRESS #ASH22 | Aaron Etra @MountSinaiNYC describes a phase II trial of itacitinib in pts with LR #GvHD vs CS. Ita treatment resulted in an 90% lower cumulative steroid dose through D28 vs SCS & fewer pts developed at least 1 serious infection within 90 days (27% vs 42%) #BMTSM
12 Dec 2022
CONGRESS #ASH22 | Amandeep Salhotra @cityofhope discusses the results of Orca-Q an investigational cell therapy in a phase I study. N = 26. The estimated incidence of grade 2-4 acute GvHD at >150 days = 8%. Patients given Orca-Q had no cases of chronic #GvHD were recorded. #BMTSM
12 Dec 2022
CONGRESS #ASH22 | Bruce Blazar @umnmedschool presents the E Donnall Thomas lecture on finding effective treatment for #GvHD & receives this year's prize. He starts with the history of the field then looks at the path to FDA approval of belumosudil, ruxo & ibrutinib #BMTSM
12 Dec 2022
Keep an eye on our Twitter page!
The @GvHD_Hub will be bringing you comprehensive updates as we continue our live coverage of #ASH22.
Sessions covered today:
The E. Donnall Thomas Lecture, 722 and 721
#hematology #medicalcongress #cancerresearch #gvhd #BMTsm
The @GvHD_Hub will be bringing you comprehensive updates as we continue our live coverage of #ASH22.
Sessions covered today:
The E. Donnall Thomas Lecture, 722 and 721
#hematology #medicalcongress #cancerresearch #gvhd #BMTsm
11 Dec 2022
Congress #ASH22 | Franco Locatelli @bambinogesu presents data from REACH4, a phase I/II study of Ruxolitinib in pediatric pts with grade II-IV treatment naïve or SR-aGvHD. N = 45. ORR in all patients was 84.4% at day 28, with a durable ORR at day 56 of 66.7% #GvHD #BMTSM
11 Dec 2022
CONGRESS #ASH22 | Leslie Kean @DFBC_PedCare describes real world evidence from pts treated with ABA +CNI/MTX vs ATG or PTCy post-allo-HCT. 7/8 MMUD recipients, OS, ABA+CNI/MTX = 87% vs ATG+CNI/MTX =58%. 8/8 MUD recipients, OS, ABA + CNI/MTX vs ATG+CNI/MTX= 86% vs 70% #GvHD #bmtsm
11 Dec 2022
CONGRESS #ASH22 | @jessie05866344 @MSKCancerCenter presents the results analysis of inhibiting RNA splicing factor RBM39. RBM39 deletion in donor T cells under either CD4- or distal Lck-cre profoundly reduced GVHD severity and improved overall survival in recipients #GvHD #BMTSM
11 Dec 2022
CONGRESS #ASH22 | Hajime Senjo @HokkaidoUnivPR describes CNI mediated inhibition of tolerance by blocking terminal differentiation of donor exhausted T-cells. In vivo, pTex-CNI contributed to dev of cGVHD & PD-1 blockade-induced anti-tumor response after allo-SCT. #GvHD #BMTSM
11 Dec 2022
CONGRESS #ASH22 | @DrSarahLindner @MSKCancerCenter is speaking about the effect of GvHD on microbial bile acids in the gut. The results in mice and humans suggest that loss of secondary bile acids & increased FXR activation may amplify T-cell driven disease such as #GvHD #BMTSM
11 Dec 2022
Keep an eye on our Twitter page!
The @GvHD_Hub will be covering the following sessions today:
701 Experimental Transplantation & 722 Allo Transplantation
Stay tuned for live updates, key insights, and interview coverage!
#ASH22 #hematology #medicalcongress #cancerresearch #gvhd
The @GvHD_Hub will be covering the following sessions today:
701 Experimental Transplantation & 722 Allo Transplantation
Stay tuned for live updates, key insights, and interview coverage!
#ASH22 #hematology #medicalcongress #cancerresearch #gvhd
10 Dec 2022
CONGRESS #ASH22 | @nagler_EBMT @sheba_medical debates HAPLO vs UCB graft sources using a case study. He states that the results of the CTN 1101 favour haplo-SCT however recent developments in CBT mean it remains a valuable option #GvHD #bmtsm
10 Dec 2022
CONGRESS #ASH22 | @DrMonzrAlMalki @cityofhope discusses the use of alternative donors in HCT particularly in the MMUD setting. He then describes current novel approaches to improve outcomes including PTCy & Aba, discussing some differences between these agents #GvHD #BMTSM
10 Dec 2022
CONGRESS #ASH22 | @spellman_s @BeTheMatch describes what is a complete HLA match using a case-based approach. He looks at the likelihood of availability by donor type by patient ethnic background including matched & mismatched unrelated, UCB & haplo related donors. #GvHD #BMTSM
10 Dec 2022
Congress #ASH22 | @SmithaSivaraman discusses clinical outcomes with omidubicel vs other alloHCT donor sources. Rates of grade II-IV acute #GvHD over the first 100 days post alloHCT were omidubicel 60% vs 32-43% for other sources. But Gr III-IV aGvHD & cGvHD were comparable #BMTSM
10 Dec 2022
CONGRESS #ASH22 | Everett Meyer @StanfordMed speaks about the results of Orca-T an immunotherapy in 151 pts. GvHD &RFS at 12 months = 70%. Gr≥ 3 aGVHD & mod/severe cGVHD rates were low at 5% & 6%, respectively, through 1 year post-transplant. NRM = 4% at 1 year #GvHD #BMTSM
10 Dec 2022
CONGRESS #ASH22 | @AlexHooverMD @umnmedschool describes the results of a phase II study using MAC regimen of PTCy, MMF & Tac. N = 125. CI of Gr II-IV aGVHD by day +100 = 16%; Gr III-IV aGVHD =4%. No gr IV GVHD recorded & there were no deaths due to #GVHD. 2 year OS = 80% #BMTSM
10 Dec 2022
CONGRESS #ASH22 |@Mohty_EBMT @Sorbonne_Univ_ presents data on MaaT013 in the EAP. N = 81 pts with SR/SD GI-aGvHD. D28 GI ORR = 56% & OS was 51% at 6 months. aGvHD response was improved in 31 patients previously treated with Ruxo as 2nd line & MaaT013 as 3rd line #GvHD #BMTSM
10 Dec 2022
10 Dec 2022
CONGRESS #ASH22 | Leslie Kean @DFBC_PedCare discusses early T-cell proliferation in pts with #aGvHD. Day+28 breakthrough CD4+ Tcell proliferation was detected in PBO pts who developed Gr2-4 aGvHD vs those who developed Gr0-1 aGvHD. No increase in pts treated with abatacept #BMTSM
10 Dec 2022
#ASH22 starts today!
The @GvHD_Hub will be covering ASH virtually & in person.
These sessions will be covered today:
722, 732 & Are Alt Donors Now Mainstream in Allo-Transplant?
Keep an eye on our Twitter page for live updates, key insights & interview coverage!
#hematology #gvhd
The @GvHD_Hub will be covering ASH virtually & in person.
These sessions will be covered today:
722, 732 & Are Alt Donors Now Mainstream in Allo-Transplant?
Keep an eye on our Twitter page for live updates, key insights & interview coverage!
#hematology #gvhd
5 Dec 2022
RT @Mohty_EBMT: The key #gvhd abstracts at #ASH22 selected by the @gvhd_hub team including @Florent_Malard @BipinSavani @nagler_EBMT…
30 Nov 2022
Get ready for #ASH22 with us!
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @GvHD_hub!
📌 https://t.co/xjpm4XJ1Jg
#ASH2022 #GvHD #medicalabstracts #cancer #cancerresearch
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @GvHD_hub!
📌 https://t.co/xjpm4XJ1Jg
#ASH2022 #GvHD #medicalabstracts #cancer #cancerresearch
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content